Skin bacteria could hold the key to safe treatments for eczema, new research suggests. 

A study led by scientists at The University of Manchester and Tokyo University of Agriculture and Technology found that harmless microbes living on our skin release powerful molecules, shutting down inflammation triggered by Staphylococcus aureus, the bacteria long known to exacerbate eczema. 

When nutrients run low, many ‘friendly’ staphylococcal species release tiny lipopeptides as they age. These lipopeptides stop keratinocytes, the skin’s frontline cells, from pumping out Interleukin-33 (IL‑33), a major driver of allergic inflammation. 

Specific types of lipopeptides (diacylated) were the most effective, while another type (monoacylated) had no effect. The molecules blocked IL‑33 from leaving the nucleus, trapping it in the perinuclear space, the gap between the inner and outer membranes of the nucleus, and preventing it from fuelling inflammation. 

The study, published in Nature Communications, could pave the way for a new class of safe, stable, non-infectious treatments that could help millions living with skin and other allergic diseases. 

“We think this is a very exciting result as lipopeptides are small, stable, non-infectious chemical structures that have the potential to be used as a topical treatment for eczema,” said study author Dr Peter Arkwright from The University of Manchester. 

“They might also be used in the future to treat other allergic diseases such as hay fever.” 

“We have previously already shown that blocking IL‑33 with a biologic drug stops eczema in the same mouse model,” added study author Professor Akane Tanaka, Tokyo University of Agriculture and Technology. 

“Now we’ve shown that bacteria can do it themselves – an exciting and potentially game-changing discovery.”